Are we hopefully very close to the end of HCV?

References (1)

1. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed- dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23. [CrossRef] Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV geno- type 1 infection. Gastroenterology 2014; 146: 736-43. [CrossRef] Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93. [CrossRef] Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for un- treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98. [CrossRef] Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88. [CrossRef] Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Impact of inter- feron free regimens on clinical and cost outcomes for chronic hep- atitis C genotype 1 patients. J Hepatol 2014; 60: 530-7. [CrossRef]